Kymera Investor Presentation Deck
Mean % Change (+/- S.E. of mean)
0
-10
-20
-30
-40
-50
-60
0
KT-474 HS: Significant Reductions in AN Counts Leading to
HISCR Responses and Significant Reductions in Pain and Pruritis
7
Mean % Change in Total
AN Counts Over Time
-27.4
-19.9
14
All HS Patients (N=12)*
Moderate to Severe (N=10)
-49.6
21
Day
-31.6
28
-45.4
-40.6
35
-46.1
-50.7
42
KYMERA Ⓒ2023 KYMERA THERAPEUTICS, INC.
% of HISCR Responders (80% CI)
80
70
8
50
9
30
20
10
0
0
7
HISCR50 Responders
30
14
25
21
Day
30
28
25
50
42
35
50
42
42
*One patient is censored for Day 35 and Day 42 since the patient started on ustekinumab, steroids and abx on Day 34.
Mean % Change (+/- S.E. of Mean)
Mean % Change (+/- S.E. of Mean)
Mean % Change in Average
Pain Over Past Week
-10
-20
-30
-40
-50
-60
-70
-80
0
-10
-20
-50
-60
-70
-80
-30 -29.1
-40
-90
0
-100
-26.9
0
7
-23.4
7
-38.7
-17
14
-41.7
-40.1
-56.1
21
Day
Mean % Change in Worst
Pruritus Over Past Week
-26.1
F-41.9
14
-48.6
-64.6
-24
28
-67.8
21
Day
-53.8
-65.7
-48.6
28
35
-59.7
-62.3
-60.1
-60.4
42
35
-53.6
-61.6
IRAK4
Patients
-68.4
42
PAGE 14View entire presentation